Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mega Genomics's Enterprise Value is HK$1,582.9 Mil.
Mega Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-18.4 Mil. Therefore, Mega Genomics's EV-to-FCF for today is -85.98.
The historical rank and industry rank for Mega Genomics's EV-to-FCF or its related term are showing as below:
HKSE:06667'
s EV-to-FCF Range Over the Past 10 Years
Min: -157.18 Med: 9.97 Max: 62.87
Current: -85.98
During the past 7 years, the highest EV-to-FCF of Mega Genomics was 62.87. The lowest was -157.18. And the median was 9.97.
HKSE:06667's EV-to-FCF is ranked worse than 100% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.47
vs HKSE:06667: -85.98
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mega Genomics's PE Ratio (TTM) for today is calculated as:
Mega Genomics's share price for today is HK$7.075.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mega Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mega Genomics EV-to-FCF Related Terms
Mega Genomics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Mega Genomics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06667 vs TMO, DHR, NTRA: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Mega Genomics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Genomics EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mega Genomics's EV-to-FCF falls into.
Mega Genomics's current Enterprise Value is HK$1,582.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mega Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-18.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mega Genomics (HKSE:06667) has a EV-to-FCF of -85.98 as of Sep. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mega Genomics and its competitors. According to the industry distribution chart, Mega Genomics ranks #999999 out of 106 companies in the Medical Diagnostics & Research industry.
Is Mega Genomics' EV-to-FCF too high?
Mega Genomics' current EV-to-FCF is -85.98. Based on the distribution chart, Mega Genomics ranks #999999 out of 106 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Mega Genomics ranks #999999 out of 106 companies for EV-to-FCF. This places Mega Genomics in the lower half of its industry. The industry median EV-to-FCF is 26.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.47, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Mega Genomics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mega Genomics's current EV-to-FCF is -85.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current EV-to-FCF is -85.98. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current EV-to-FCF is -85.98 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mega Genomics (HKSE:06667) Overvalued in 2026?
Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued.
The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92.
GuruFocus considers Mega Genomics to be Possible Value Trap.
Key valuation signals for HKSE:06667:
EV-to-FCF: -85.98
GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score
Get the complete analysis for HKSE:06667
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06667 has been successfully added to your 
